Press release

Hansa Biopharma AB: Hansa at Truist Securities, Stifel, and SEB Healthcare conferences

Lund, Sweden, November 5. Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, and Evan Ballantyne, CFO, will be attending the 2025 Truist Securities Biopharma Symposium in New York, Thursday 6 November. In addition, Aguiar-Lucander will be presenting at two other key industry events, the Stifel 2025 Healthcare Conference in New York, Tuesday 11 November, and the SEB Healthcare Seminar 2025, in Stockholm, Thursday 13 November.

If you are interested in meeting with Hansa's management for one-on-one meetings, please contact Hansa Biopharma at ir@hansabiopharma.com.

Event: 2025 Truist Securities Biopharma Symposium

Date and Place: Thursday 6 November, Lotte New York Palace Hotel, New York.

Event: Stifel 2025 Healthcare Conference

Date, Time, and Place: Tuesday 11 November, 16:00 PM EST, Lotte New York Palace Hotel, New York.

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

Webcast Link: Click here for webcast

Event: SEB Healthcare Seminar 2025 - Fireside chat & Q&A

Date, Time, and Place: Thursday 13 November, 14:20-15:00 PM CET, Kungsträdgården, Stockholm.

Moderator: Christopher Uhde, Senior Pharma & Biotech Equity Analyst, SEB

Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma

--- ENDS ---

Contacts for more information:

Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Kerstin Falck, VP Global Corporate Affairs
media@hansabiopharma.com

Notes to editors

About Hansa Biopharma

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.